查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585696

出血性疾病治疗市场：按疾病类型、药物类别、分销管道划分 - 全球预测 2025-2030

Bleeding Disorders Treatment Market by Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease), Drug Class (Antibrinolytics, Desmopressin, Fibrin Sealant), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年出血性疾病治疗市场价值为135.6亿美元，预计到2024年将达到148亿美元，复合年增长率为9.29%，到2030年将达到252.5亿美元。

出血性疾病治疗市场包括广泛的产品和服务，旨在管理因人体凝血机制缺陷或故障而导致异常或过度出血的疾病。由于血友病、血管性血友病和其他罕见出血性疾病等疾病的需要，该领域的应用涵盖医院、专科诊所和居家医疗，最终用途包括有效且方便的治疗选择。根据市场洞察，意识的提高、重组基因技术的进步以及主动降低出血风险的预防性治疗的快速采用正在推动市场的强劲增长。此外，政府支持和有利的报销政策进一步支持市场扩张。基因疗法和非替代疗法的整合带来了最近的商机，为製药业的伙伴关係和创新提供了空间。然而，挑战仍然存在，例如治疗成本上升、监管要求更严格以及新兴市场获得治疗的机会有限，这可能会阻碍市场扩张。在创新方面，半衰期延长的凝血因子、基因编辑技术和根据个人基因特征定制治疗的个人化医疗方法等领域提供了潜在的成长途径。公司可以透过专注于提高便利性和合规性的技术来受益，例如开发易于使用的交付系统和用于监控和管理的行动应用程式。出血性疾病治疗市场的特点是发展迅速、竞争激烈，需要持续的研发投资。简而言之，产业相关人员必须保持敏捷，加强研发力量，建立策略联盟以抓住市场占有率机会，同时利用需要解决的现有障碍。

主要市场统计
基准年[2023] 135.6亿美元
预测年份 [2024] 148亿美元
预测年份 [2030] 252.5亿美元
复合年增长率（%） 9.29%

市场动态：揭示快速发展的出血性疾病治疗市场的关键市场洞察

供需的动态交互作用正在改变出血性疾病治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 肝损伤和贫血的盛行率增加
    • 政府增加医疗保健支出
    • 显着改善每个国家获得医疗保健的机会
  • 市场限制因素
    • 缺乏熟练的专业人员和训练有素的专业知识
  • 市场机会
    • 提高对出血性疾病的认识
    • 由于感染风险降低和研发投资增加，需求增加
  • 市场问题
    • 出血性疾病治疗药价高

波特五力：开拓出血性疾病治疗市场的策略工具

波特的五力架构是了解出血性疾病治疗市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解出血性疾病治疗市场的外部影响

外部宏观环境因素在塑造出血性疾病治疗市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解出血性疾病治疗市场的竞争格局

出血性疾病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵出血性疾病治疗市场供应商的绩效评估

FPNV 定位矩阵是评估出血性疾病治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製出血性疾病治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对出血性疾病治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肝病和贫血盛行率增加
      • 政府医疗费用支出增加
      • 经济中获得医疗保健的机会显着改善
    • 抑制因素
      • 缺乏熟练的专业人员和训练有素的专业知识
    • 机会
      • 提高对出血性疾病的认识
      • 由于感染风险降低以及研发方面的大量投资，需求增加
    • 任务
      • 治疗出血性疾病的药物成本很高
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章出血性疾病治疗市场：依疾病类型

  • 介绍
  • A型血友病
  • B型血友病
  • 血管性血友病

第七章出血性疾病治疗市场：依药物类别

  • 介绍
  • 抗溶药物
  • 去氨加压素
  • 纤维蛋白胶
  • 血浆衍生凝血因子浓缩物
  • 重组凝血因子浓缩物

第八章出血性疾病治疗市场：依分销管道划分

  • 介绍
  • 配药房
  • 医院药房
  • 零售药房

第 9 章：美洲出血性疾病治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太出血性疾病治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章：欧洲、中东和非洲出血性疾病治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Behring
  • Emergent BioSolutions Inc.
  • Grifols International, SA
  • Kedrion SpA
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Xenetic Biosciences, Inc.
Product Code: MRR-437D45957F02

The Bleeding Disorders Treatment Market was valued at USD 13.56 billion in 2023, expected to reach USD 14.80 billion in 2024, and is projected to grow at a CAGR of 9.29%, to USD 25.25 billion by 2030.

The market for bleeding disorders treatment encompasses a wide range of products and services aimed at managing conditions characterized by abnormal or excessive bleeding due to deficiencies or dysfunctions in the body's clotting mechanism. Necessitated by conditions such as hemophilia, von Willebrand disease, and other rare bleeding disorders, the field's application spans across hospitals, specialty clinics, and home-care settings, with significant end-use coming from healthcare institutions and individuals seeking effective and convenient treatment options. The market insights reveal robust growth driven by increased awareness, advancements in recombinant technology, and a surge in prophylactic treatment adoption, which mitigates bleeding risks before they occur. Moreover, government support and favorable reimbursement policies further propel market expansion. Recent opportunities are presented by the integration of gene therapies and non-replacement therapies, offering room for partnerships and innovation within pharmaceutical circles. However, the market still faces challenges such as high treatment costs, stringent regulatory requirements, and limited access to treatment in developing regions, which could hinder expansion. In terms of innovation, areas such as extended half-life clotting factors, gene editing technologies, and personalized medicine approaches to tailor treatments to individual genetic profiles represent potential growth avenues. Businesses could benefit by focusing on technology that improves convenience and compliance, such as developing user-friendly delivery systems and mobile applications for monitoring and management. The bleeding disorders treatment market is characterized by rapid advancements and a competitive landscape, necessitating continuous research and development investments. In essence, industry stakeholders need to maintain agility, bolster their R&D wings, and develop strategic alliances to capture growth opportunities, while addressing prevailing barriers to maximize their market share efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 13.56 billion
Estimated Year [2024] USD 14.80 billion
Forecast Year [2030] USD 25.25 billion
CAGR (%) 9.29%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bleeding Disorders Treatment Market

The Bleeding Disorders Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the prevalence of liver disorders and anemia
    • Rising healthcare expenditure by the government
    • Considerable increase in healthcare accessibility in economies
  • Market Restraints
    • Lack of skilled professionals and trained expertise
  • Market Opportunities
    • Rising awareness regarding bleeding disorders
    • Rise in demand due to lower infection risks and high investments in research and development
  • Market Challenges
    • High cost of medications of bleeding disorders treatment

Porter's Five Forces: A Strategic Tool for Navigating the Bleeding Disorders Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bleeding Disorders Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bleeding Disorders Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bleeding Disorders Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bleeding Disorders Treatment Market

A detailed market share analysis in the Bleeding Disorders Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bleeding Disorders Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bleeding Disorders Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bleeding Disorders Treatment Market

A strategic analysis of the Bleeding Disorders Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, CSL Behring, Emergent BioSolutions Inc., Grifols International, S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., and Xenetic Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hemophilia A, Hemophilia B, and Von Willebrand Disease.
  • Based on Drug Class, market is studied across Antibrinolytics, Desmopressin, Fibrin Sealant, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.
  • Based on Distribution Channel, market is studied across Compounding Pharmacies, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of liver disorders and anemia
      • 5.1.1.2. Rising healthcare expenditure by the government
      • 5.1.1.3. Considerable increase in healthcare accessibility in economies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled professionals and trained expertise
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising awareness regarding bleeding disorders
      • 5.1.3.2. Rise in demand due to lower infection risks and high investments in research and development
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of medications of bleeding disorders treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bleeding Disorders Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hemophilia A
  • 6.3. Hemophilia B
  • 6.4. Von Willebrand Disease

7. Bleeding Disorders Treatment Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antibrinolytics
  • 7.3. Desmopressin
  • 7.4. Fibrin Sealant
  • 7.5. Plasma Derived Coagulation Factor Concentrates
  • 7.6. Recombinant Coagulation Factor Concentrates

8. Bleeding Disorders Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Compounding Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Bleeding Disorders Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bleeding Disorders Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorders Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alnylam Pharmaceuticals Inc.
  • 2. Amgen Inc.
  • 3. Baxter International Inc.
  • 4. Bayer AG
  • 5. Biogen Inc.
  • 6. Bristol-Myers Squibb Company
  • 7. CSL Behring
  • 8. Emergent BioSolutions Inc.
  • 9. Grifols International, S.A.
  • 10. Kedrion S.p.A.
  • 11. Novo Nordisk A/S
  • 12. Octapharma AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Xenetic Biosciences, Inc.

LIST OF FIGURES

  • FIGURE 1. BLEEDING DISORDERS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BLEEDING DISORDERS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLEEDING DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLEEDING DISORDERS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTIBRINOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY FIBRIN SEALANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COMPOUNDING PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023